Abingworth LLP Activity Q4 2010-Q4 2022

Q4 2022

			Value		Shares		↓ Weighting
PCVX	Sell	VAXCYTE INC	$96,813,783	-3.2%	2,019,057	-51.6%	31.54%	-7.8%

Q3 2022

			Value		Shares		↓ Weighting
SPRB	New	SPRUCE BIOSCIENCES INC	$2,474,000	–	1,792,518	–	0.85%	–
	New	SOLENO THERAPEUTICS INC	$2,007,000	–	1,201,506	–	0.69%	–
	New	EXICURE INC	$439,000	–	281,636	–	0.15%	–
HSGX	Exit	Ocugen	$0	–	-7,111	–	-0.01%	–
XCUR	Exit	Exicure	$0	–	-281,636	–	-0.19%	–
	Exit	Spruce Bio	$0	–	-1,792,518	–	-0.99%	–
SLNO	Exit	Soleno	$0	–	-18,022,602	–	-1.01%	–
SRRA	Exit	Sierra Oncology	$0	–	-1,314,127	–	-23.14%	–

Q2 2022

			Value		Shares		↓ Weighting
PCVX	New	Vaxcyte	$90,711,000	–	4,168,718	–	29.04%	–
SRRA	New	Sierra Oncology	$72,277,000	–	1,314,127	–	23.14%	–
VERA	New	Vera	$40,289,000	–	2,960,231	–	12.90%	–
ACET	New	Adicet	$30,885,000	–	2,115,385	–	9.89%	–
	New	Hillevax	$19,929,000	–	1,838,486	–	6.38%	–
PHAT	New	Phathom	$12,112,000	–	1,435,106	–	3.88%	–
	New	Jasper	$10,638,000	–	5,628,558	–	3.40%	–
VRNA	New	Veronasponds adr	$10,174,000	–	2,457,500	–	3.26%	–
	New	eFFECTOR	$6,462,000	–	4,822,114	–	2.07%	–
RPHM	New	Reneo	$5,413,000	–	2,073,957	–	1.73%	–
SLNO	New	Soleno	$3,165,000	–	18,022,602	–	1.01%	–
	New	Spruce Bio	$3,101,000	–	1,792,518	–	0.99%	–
NCNA	New	Nucanaadr	$2,417,000	–	3,333,333	–	0.77%	–
PRTK	New	Paratek	$1,999,000	–	1,041,131	–	0.64%	–
SIEN	New	Sientra	$1,389,000	–	1,673,589	–	0.44%	–
XCUR	New	Exicure	$594,000	–	281,636	–	0.19%	–
CBAY	New	Cymabay	$385,000	–	131,036	–	0.12%	–
MTEM	New	Molecular Templates	$182,000	–	200,000	–	0.06%	–
OBSV	New	Obseva	$141,000	–	87,999	–	0.04%	–
AGLE	New	Aeglea	$121,000	–	240,500	–	0.04%	–
HSGX	New	Ocugen	$16,000	–	7,111	–	0.01%	–

Q4 2021

			Value		Shares		↓ Weighting
HSGX	Exit	Ocugen	$0	–	-7,111	–	-0.01%	–
OBSV	Exit	Obseva	$0	–	-87,999	–	-0.06%	–
CBAY	Exit	Cymabay	$0	–	-131,036	–	-0.11%	–
MTEM	Exit	Molecular Templates	$0	–	-200,000	–	-0.30%	–
AGLE	Exit	Aeglea	$0	–	-240,500	–	-0.43%	–
PRTK	Exit	Paratek	$0	–	-1,041,131	–	-1.15%	–
XCUR	Exit	Exicure	$0	–	-6,977,000	–	-1.87%	–
NCNA	Exit	Nucanaadr	$0	–	-3,333,333	–	-1.94%	–
SLNO	Exit	Soleno	$0	–	-10,302,602	–	-2.16%	–
	Exit	Spruce Bio	$0	–	-1,792,518	–	-2.43%	–
ACET	Exit	Adicet	$0	–	-1,615,385	–	-2.87%	–
VRNA	Exit	Veronasponds adr	$0	–	-2,457,499	–	-3.04%	–
SIEN	Exit	Sientra	$0	–	-2,349,827	–	-3.06%	–
RPHM	Exit	Reneo	$0	–	-2,073,957	–	-3.47%	–
SRRA	Exit	Sierra Oncology	$0	–	-876,656	–	-4.32%	–
PHAT	Exit	Phathom	$0	–	-1,203,135	–	-8.74%	–
VERA	Exit	Vera	$0	–	-2,960,231	–	-11.66%	–
	Exit	Jasper	$0	–	-5,628,558	–	-13.17%	–
	Exit	eFFECTOR	$0	–	-4,822,114	–	-15.21%	–
PCVX	Exit	Vaxcyte	$0	–	-4,168,718	–	-24.00%	–

Q3 2021

			Value		Shares		↓ Weighting
	New	eFFECTOR	$67,027,000	–	4,822,114	–	15.21%	–
	New	Jasper	$58,030,000	–	5,628,558	–	13.17%	–
SRRA	Buy	Sierra Oncology	$19,031,000	+13.2%	876,656	+0.6%	4.32%	-16.9%
RPHM	Buy	Reneo	$15,306,000	-15.9%	2,073,957	+5.7%	3.47%	-38.2%
SIEN	Sell	Sientra	$13,465,000	-29.2%	2,349,827	-1.7%	3.06%	-48.1%
XFOR	Exit	X4 Pharma	$0	–	-229,885	–	-0.46%	–

Q2 2021

			Value		Shares		↓ Weighting
PCVX	New	Vaxcyte	$93,629,000	–	4,168,718	–	28.94%	–
PHAT	New	Phathom	$40,726,000	–	1,203,135	–	12.59%	–
VERA	New	Vera	$38,513,000	–	2,960,231	–	11.90%	–
	New	Spruce Bio	$20,076,000	–	1,792,518	–	6.21%	–
SIEN	New	Sientra	$19,031,000	–	2,390,843	–	5.88%	–
RPHM	New	Reneo	$18,190,000	–	1,962,221	–	5.62%	–
SRRA	New	Sierra Oncology	$16,813,000	–	871,125	–	5.20%	–
ACET	New	Adicet	$16,574,000	–	1,615,385	–	5.12%	–
VRNA	New	Veronasponds adr	$15,998,000	–	2,457,499	–	4.94%	–
SLNO	New	Soleno	$11,642,000	–	10,302,602	–	3.60%	–
XCUR	New	Exicure	$10,396,000	–	6,977,000	–	3.21%	–
NCNA	New	Nucanaadr	$9,200,000	–	3,333,333	–	2.84%	–
PRTK	New	Paratek	$7,090,000	–	1,041,131	–	2.19%	–
AGLE	New	Aeglea	$1,671,000	–	240,500	–	0.52%	–
MTEM	New	Molecular Templates	$1,564,000	–	200,000	–	0.48%	–
XFOR	New	X4 Pharma	$1,494,000	–	229,885	–	0.46%	–
CBAY	New	Cymabay	$571,000	–	131,036	–	0.18%	–
OBSV	New	Obseva	$266,000	–	87,999	–	0.08%	–
HSGX	New	Ocugen	$57,000	–	7,111	–	0.02%	–

Q4 2020

			Value		Shares		↓ Weighting
HSGX	Exit	Ocugen	$0	–	-7,111	–	0.00%	–
OBSV	Exit	Obseva	$0	–	-87,999	–	-0.05%	–
PRTO	Exit	Protara	$0	–	-20,610	–	-0.07%	–
CBAY	Exit	Cymabay	$0	–	-131,036	–	-0.20%	–
AGLE	Exit	Aeglea	$0	–	-240,500	–	-0.36%	–
MTEM	Exit	Molecular Templates	$0	–	-200,000	–	-0.47%	–
PRTK	Exit	Paratek	$0	–	-1,041,131	–	-1.20%	–
SIEN	Exit	Sientra	$0	–	-2,390,843	–	-1.74%	–
SRRA	Exit	Sierra Oncology	$0	–	-876,541	–	-1.97%	–
XCUR	Exit	Exicure	$0	–	-6,977,000	–	-2.58%	–
VRNA	Exit	Veronasponds adr	$0	–	-2,457,499	–	-3.28%	–
NCNA	Exit	Nucanaads	$0	–	-3,333,333	–	-3.69%	–
CRSP	Exit	Crisprnamen akt	$0	–	-259,599	–	-4.64%	–
SLNO	Exit	Soleno	$0	–	-10,302,602	–	-5.51%	–
PHAT	Exit	Phathom	$0	–	-1,203,135	–	-9.52%	–
PSNL	Exit	Personalis	$0	–	-4,462,452	–	-20.68%	–
PCVX	Exit	Vaxcyte	$0	–	-4,168,718	–	-44.03%	–

Q3 2020

			Value		Shares		↓ Weighting
PSNL	Sell	Personalis	$96,701,000	+36.9%	4,462,452	-18.1%	20.68%	+4.8%
CRSP	Sell	Crisprnamen akt	$21,684,000	-43.0%	259,599	-50.0%	4.64%	-56.4%
NCNA	New	Nucanaads	$17,233,000	–	3,333,333	–	3.69%	–
VRNA	Buy	Veronasponds adr	$15,335,000	+263.3%	2,457,499	+172.5%	3.28%	+178.0%
PRTO	New	Protara	$344,000	–	20,610	–	0.07%	–
TARA	Exit	Protara	$0	–	-53,612	–	-0.84%	–

Q2 2020

			Value		Shares		↓ Weighting
PCVX	New	Vaxcyte	$131,523,000	–	4,168,718	–	36.77%	–
PSNL	New	Personalis	$70,623,000	–	5,449,294	–	19.75%	–
PHAT	New	Phathom	$39,367,000	–	1,203,135	–	11.01%	–
CRSP	New	Crisprnamen akt	$38,062,000	–	519,198	–	10.64%	–
SLNO	New	Soleno	$22,769,000	–	10,302,602	–	6.37%	–
XCUR	New	Exicure	$16,954,000	–	6,977,000	–	4.74%	–
SRRA	New	Sierra Oncology	$10,536,000	–	876,541	–	2.95%	–
SIEN	New	Sientra	$9,229,000	–	2,390,843	–	2.58%	–
PRTK	New	Paratek	$5,424,000	–	1,041,131	–	1.52%	–
VRNA	New	Veronasponds adr	$4,221,000	–	901,943	–	1.18%	–
TARA	New	Protara	$3,001,000	–	53,612	–	0.84%	–
MTEM	New	Molecular Templates	$2,758,000	–	200,000	–	0.77%	–
AGLE	New	Aeglea	$2,221,000	–	240,500	–	0.62%	–
OBSV	New	Obseva	$517,000	–	87,999	–	0.14%	–
CBAY	New	Cymabay	$456,000	–	131,036	–	0.13%	–
HSGX	New	Ocugen	$2,000	–	7,111	–	0.00%	–

Q4 2019

			Value		Shares		↓ Weighting
HSGX	Exit	Ocugen	$0	–	-7,111	–	-0.01%	–
SRRA	Exit	Sierra Oncology	$0	–	-216,667	–	-0.05%	–
PRTO	Exit	Proteon	$0	–	-2,017,872	–	-0.33%	–
CBAY	Exit	Cymabay	$0	–	-131,036	–	-0.42%	–
OBSV	Exit	Obseva	$0	–	-87,999	–	-0.46%	–
CHMA	Exit	Chiasma	$0	–	-370,671	–	-1.16%	–
AGLE	Exit	Aeglea	$0	–	-240,500	–	-1.17%	–
VRNA	Exit	Veronasponds adr	$0	–	-901,943	–	-2.61%	–
PRTK	Exit	Paratek	$0	–	-1,041,131	–	-2.85%	–
SLNO	Exit	Soleno	$0	–	-4,669,272	–	-4.37%	–
SIEN	Exit	Sientra	$0	–	-2,390,843	–	-9.78%	–
XCUR	Exit	Exicure	$0	–	-6,250,000	–	-9.96%	–
CRSP	Exit	Crisprnamen akt	$0	–	-628,398	–	-16.28%	–
PSNL	Exit	Personalis	$0	–	-5,449,294	–	-50.55%	–

Q3 2019

			Value		Shares		↓ Weighting
CRSP	Sell	Crisprnamen akt	$25,745,000	-53.2%	628,398	-46.3%	16.28%	-22.9%
XCUR	New	Exicure	$15,750,000	–	6,250,000	–	9.96%	–
CHMA	Sell	Chiasma	$1,827,000	-48.7%	370,671	-22.5%	1.16%	-15.3%
HSGX	Sell	Ocugen	$20,000	-76.2%	7,111	-98.3%	0.01%	-59.4%
AVDR	Exit	Avedro	$0	–	-719,402	–	-5.40%	–

Q2 2019

			Value		Shares		↓ Weighting
PSNL	New	Personalis	$147,948,000	–	5,449,294	–	56.74%	–
CRSP	New	Crisprnamen akt	$55,050,000	–	1,171,268	–	21.11%	–
SIEN	New	Sientra	$14,704,000	–	2,390,843	–	5.64%	–
AVDR	New	Avedro	$14,086,000	–	719,402	–	5.40%	–
SLNO	New	Soleno	$12,140,000	–	4,669,272	–	4.66%	–
VRNA	New	Veronasponds adr	$4,537,000	–	901,943	–	1.74%	–
PRTK	New	Paratek	$4,123,000	–	1,041,131	–	1.58%	–
CHMA	New	Chiasma	$3,558,000	–	478,206	–	1.36%	–
AGLE	New	Aeglea	$1,638,000	–	240,500	–	0.63%	–
OBSV	New	Obseva	$985,000	–	87,999	–	0.38%	–
CBAY	New	Cymabay	$937,000	–	131,036	–	0.36%	–
PRTO	New	Proteon	$851,000	–	2,017,872	–	0.33%	–
SRRA	New	Sierra Oncology	$121,000	–	216,667	–	0.05%	–
HSGX	New	Histogenics	$84,000	–	426,666	–	0.03%	–

Q4 2018

			Value		Shares		↓ Weighting
HSGX	Exit	Histogenix	$0	–	-888,889	–	-0.28%	–
IMDZ	Exit	Immune Design	$0	–	-352,300	–	-0.71%	–
AVEO	Exit	Aveo Pharma	$0	–	-400,000	–	-0.78%	–
SRRA	Exit	Sierra Oncology	$0	–	-1,444,445	–	-1.46%	–
AUPH	Exit	Aurinia Pharma	$0	–	-400,434	–	-1.58%	–
CLLS	Exit	Cellectissponds adr	$0	–	-100,000	–	-1.68%	–
RARE	Exit	Ultragenyx	$0	–	-38,100	–	-1.73%	–
CBAY	Exit	Cymabay	$0	–	-273,417	–	-1.80%	–
ADAP	Exit	Adaptimmunesponds adr	$0	–	-250,000	–	-2.02%	–
PRTO	Exit	Proteon	$0	–	-2,017,872	–	-2.28%	–
CHMA	Exit	Chiasma	$0	–	-2,080,595	–	-4.45%	–
OBSV	Exit	Obseva	$0	–	-440,000	–	-4.72%	–
PRTK	Exit	Paratek	$0	–	-1,041,131	–	-5.97%	–
VRNA	Exit	Veronasponds adr	$0	–	-901,943	–	-6.70%	–
SIEN	Exit	Sientra	$0	–	-2,199,012	–	-31.22%	–
CRSP	Exit	Crisprnamen akt	$0	–	-1,237,202	–	-32.62%	–

Q3 2018

			Value		Shares		↓ Weighting
SIEN	Sell	Sientra	$52,512,000	+8.7%	2,199,012	-11.3%	31.22%	+13.1%
VRNA	New	Veronasponds adr	$11,274,000	–	901,943	–	6.70%	–
GTXI	Exit	GTX	$0	–	-339,174	–	-2.97%	–

Q2 2018

			Value		Shares		↓ Weighting
CRSP	New	Crisprnamen akt	$72,698,000	–	1,237,202	–	41.53%	–
SIEN	New	Sientra	$48,320,000	–	2,480,494	–	27.60%	–
PRTK	New	Paratek	$10,567,000	–	1,041,131	–	6.04%	–
OBSV	New	Obseva	$6,662,000	–	440,000	–	3.81%	–
GTXI	New	GTX	$5,196,000	–	339,174	–	2.97%	–
PRTO	New	Proteon	$4,843,000	–	2,017,872	–	2.77%	–
SRRA	New	Sierra Oncology	$4,276,000	–	1,444,445	–	2.44%	–
CBAY	New	Cymabay	$3,667,000	–	273,417	–	2.10%	–
CHMA	New	Chiasma	$3,121,000	–	2,080,595	–	1.78%	–
ADAP	New	Adaptimmunesponds adr	$2,965,000	–	250,000	–	1.69%	–
RARE	New	Ultragenyx	$2,928,000	–	38,100	–	1.67%	–
CLLS	New	Cellectissponds adr	$2,825,000	–	100,000	–	1.61%	–
AUPH	New	Aurinia Pharma	$2,250,000	–	400,434	–	1.28%	–
HSGX	New	Histogenix	$2,204,000	–	888,889	–	1.26%	–
IMDZ	New	Immune Design	$1,621,000	–	352,300	–	0.93%	–
AVEO	New	Aveo Pharma	$900,000	–	400,000	–	0.51%	–

Q4 2017

			Value		Shares		↓ Weighting
INNL	Exit	Innocoll CVRcvr	$0	–	-537,235	–	-0.22%	–
EVAR	Exit	Lombard Medical	$0	–	-3,473,452	–	-1.06%	–
AUPH	Exit	Aurinia Pharma	$0	–	-252,129	–	-1.10%	–
HSGX	Exit	Histogenix	$0	–	-888,889	–	-1.22%	–
DERM	Exit	Dermira	$0	–	-70,000	–	-1.31%	–
RARE	Exit	Ultragenyx	$0	–	-38,100	–	-1.40%	–
ADAP	Exit	Adaptimmunesponds adr	$0	–	-250,000	–	-1.42%	–
GTXI	Exit	GTX	$0	–	-339,174	–	-1.92%	–
CLLS	Exit	Cellectissponds adr	$0	–	-100,000	–	-1.97%	–
OBSV	Exit	Obseva	$0	–	-440,000	–	-2.41%	–
IMDZ	Exit	Immune Design	$0	–	-352,300	–	-2.52%	–
CASC	Exit	Cascadian	$0	–	-925,000	–	-2.62%	–
PRTO	Exit	Proteon	$0	–	-2,017,872	–	-2.72%	–
CHMA	Exit	Chiasma	$0	–	-2,080,595	–	-3.67%	–
CBAY	Exit	Cymabay	$0	–	-1,542,722	–	-8.60%	–
PRTK	Exit	Paratek	$0	–	-1,041,131	–	-18.09%	–
SIEN	Exit	Sientra	$0	–	-2,199,012	–	-23.42%	–
CRSP	Exit	Crisprnamen akt	$0	–	-1,971,907	–	-24.33%	–

Q3 2017

			Value		Shares		↓ Weighting
CRSP	Sell	Crisprnamen akt	$35,139,000	-9.8%	1,971,907	-19.3%	24.33%	-21.6%
PRTK	Sell	Paratek	$26,132,000	-16.4%	1,041,131	-19.9%	18.09%	-27.3%
CBAY	Sell	Cymabay	$12,419,000	+34.8%	1,542,722	-3.6%	8.60%	+17.2%
OBSV	New	Obseva	$3,480,000	–	440,000	–	2.41%	–
GTXI	New	GTX	$2,781,000	–	339,174	–	1.92%	–
RARE	New	Ultragenyx	$2,029,000	–	38,100	–	1.40%	–
INNL	New	Innocoll CVRcvr	$322,000	–	537,235	–	0.22%	–
NOVN	Exit	Novan	$0	–	-53,367	–	-0.17%	–
INNL	Exit	Innocollsponds adr	$0	–	-537,235	–	-0.97%	–

Q2 2017

			Value		Shares		↓ Weighting
CRSP	New	Crisprnamen akt	$38,970,000	–	2,444,809	–	31.01%	–
PRTK	New	Paratek	$31,275,000	–	1,300,432	–	24.89%	–
SIEN	New	Sientra	$21,330,000	–	2,199,012	–	16.98%	–
CBAY	New	Cymabay	$9,216,000	–	1,600,000	–	7.33%	–
CASC	New	Cascadian	$3,432,000	–	925,000	–	2.73%	–
IMDZ	New	Immune Design	$3,400,000	–	352,300	–	2.71%	–
PRTO	New	Proteon	$3,027,000	–	2,017,872	–	2.41%	–
CHMA	New	Chiasma	$2,913,000	–	2,080,595	–	2.32%	–
CLLS	New	Cellectissponds adr	$2,566,000	–	100,000	–	2.04%	–
DERM	New	Dermira	$2,038,000	–	70,000	–	1.62%	–
EVAR	New	Lombard Medical	$1,806,000	–	3,473,452	–	1.44%	–
HSGX	New	Histogenix	$1,582,000	–	888,889	–	1.26%	–
AUPH	New	Aurinia Pharma	$1,543,000	–	252,129	–	1.23%	–
INNL	New	Innocollsponds adr	$1,220,000	–	537,235	–	0.97%	–
ADAP	New	Adaptimmunesponds adr	$1,125,000	–	250,000	–	0.90%	–
NOVN	New	Novan	$215,000	–	53,367	–	0.17%	–

Q4 2016

			Value		Shares		↓ Weighting
OGXI	Exit	Oncogenex Pharma	$0	–	-396,104	–	-0.19%	–
HSGX	Exit	Histogenix	$0	–	-176,904	–	-0.52%	–
RGLS	Exit	Regulus	$0	–	-327,350	–	-1.04%	–
AUPH	Exit	Anthera	$0	–	-437,994	–	-1.32%	–
IMDZ	Exit	Immune Design	$0	–	-197,300	–	-1.43%	–
ANTH	Exit	Aurinia Pharma	$0	–	-512,036	–	-1.47%	–
ADAP	Exit	Adaptimmunesponds adr	$0	–	-250,000	–	-1.69%	–
SENS	Exit	Senseonics	$0	–	-516,882	–	-1.92%	–
DERM	Exit	Dermira	$0	–	-70,000	–	-2.27%	–
CLLS	Exit	Cellectissponds adr	$0	–	-100,000	–	-2.31%	–
CBAY	Exit	Cymabay	$0	–	-1,600,000	–	-2.98%	–
EVAR	Exit	Lombard Medical	$0	–	-3,473,452	–	-3.07%	–
INNL	Exit	Innocollsponds adr	$0	–	-555,555	–	-3.09%	–
NOVN	Exit	Novan	$0	–	-200,000	–	-3.86%	–
DRNA	Exit	Dicerna	$0	–	-945,757	–	-5.33%	–
CHMA	Exit	Chiasma	$0	–	-2,080,595	–	-5.84%	–
CEMP	Exit	Cempra	$0	–	-383,935	–	-8.90%	–
PRTK	Exit	Paratek	$0	–	-1,301,413	–	-16.22%	–
PRTO	Exit	Proteon	$0	–	-2,017,872	–	-17.62%	–
SIEN	Exit	Sientra	$0	–	-2,199,012	–	-18.95%	–

Q3 2016

			Value		Shares		↓ Weighting
NOVN	New	Novan	$4,032,000	–	200,000	–	3.86%	–
ANTH	Buy	Aurinia Pharma	$1,531,000	+13.5%	512,036	+16.9%	1.47%	+3.8%
AUPH	Sell	Anthera	$1,375,000	-0.9%	437,994	-14.5%	1.32%	-9.3%
HSGX	New	Histogenix	$543,000	–	176,904	–	0.52%	–
EPRSQ	Exit	Epirus Biopharma	$0	–	-7,896	–	-0.00%	–
TBRA	Exit	Tobira	$0	–	-589,244	–	-7.72%	–

Q2 2016

			Value		Shares		↓ Weighting
PRTK	New	Paratek	$18,103,000	–	1,301,413	–	18.96%	–
PRTO	New	Proteon	$16,264,000	–	2,017,872	–	17.03%	–
SIEN	New	Sientra	$14,470,000	–	2,199,012	–	15.15%	–
TBRA	New	Tobira	$7,377,000	–	589,244	–	7.72%	–
CEMP	New	Cempra	$6,331,000	–	383,935	–	6.63%	–
CHMA	New	Chiasma	$6,013,000	–	2,080,595	–	6.30%	–
EVAR	New	Lombard Medical	$3,786,000	–	3,473,452	–	3.96%	–
INNL	New	Innocollsponds adr	$3,067,000	–	555,555	–	3.21%	–
DRNA	New	Dicerna	$2,828,000	–	945,757	–	2.96%	–
CBAY	New	Cymabay	$2,800,000	–	1,600,000	–	2.93%	–
CLLS	New	Cellectissponds adr	$2,659,000	–	100,000	–	2.78%	–
DERM	New	Dermira	$2,047,000	–	70,000	–	2.14%	–
ADAP	New	Adaptimmunesponds adr	$2,033,000	–	250,000	–	2.13%	–
SENS	New	Senseonics	$2,026,000	–	516,882	–	2.12%	–
IMDZ	New	Immune Design	$1,610,000	–	197,300	–	1.69%	–
AUPH	New	Aurinia Pharma	$1,388,000	–	512,036	–	1.45%	–
ANTH	New	Anthera	$1,349,000	–	437,994	–	1.41%	–
RGLS	New	Regulus	$943,000	–	327,350	–	0.99%	–
OGXI	New	Oncogenex Pharma	$400,000	–	396,104	–	0.42%	–
EPRSQ	New	Epirus Biopharma	$4,000	–	7,896	–	0.00%	–

Q4 2015

			Value		Shares		↓ Weighting
EPRSQ	Exit	Epirus Biopharma	$0	–	-7,896	–	-0.02%	–
FLKS	Exit	Flex Pharma	$0	–	-10,000	–	-0.07%	–
CCXI	Exit	Chemocentryx	$0	–	-215,000	–	-0.76%	–
OGXI	Exit	Oncogenex Pharma	$0	–	-603,740	–	-0.78%	–
DERM	Exit	Dermira	$0	–	-70,000	–	-0.95%	–
RGLS	Exit	Regulus	$0	–	-327,350	–	-1.25%	–
ANTH	Exit	Anthera	$0	–	-437,994	–	-1.56%	–
CBAY	Exit	Cymabay	$0	–	-1,600,000	–	-1.79%	–
TBRA	Exit	Tobiraspons adr	$0	–	-589,244	–	-3.30%	–
INNL	Exit	Innocoll	$0	–	-555,555	–	-3.91%	–
DRNA	Exit	Dicerna	$0	–	-945,757	–	-4.53%	–
CEMP	Exit	Cempra	$0	–	-383,935	–	-6.24%	–
EVAR	Exit	Lombard Medical	$0	–	-3,473,452	–	-7.20%	–
SIEN	Exit	Sientra	$0	–	-2,199,012	–	-13.04%	–
PRTK	Exit	Paratek	$0	–	-1,301,413	–	-14.43%	–
PRTO	Exit	Proteon	$0	–	-2,017,872	–	-16.02%	–
CHMA	Exit	Chiasma	$0	–	-2,080,595	–	-24.16%	–

Q3 2015

			Value		Shares		↓ Weighting
CHMA	New	Chiasma	$41,362,000	–	2,080,595	–	24.16%	–
CEMP	Sell	Cempra	$10,685,000	-27.5%	383,935	-10.5%	6.24%	-6.7%
CBAY	New	Cymabay	$3,072,000	–	1,600,000	–	1.79%	–
DERM	New	Dermira	$1,624,000	–	70,000	–	0.95%	–
EPRSQ	New	Epirus Biopharma	$35,000	–	7,896	–	0.02%	–
ZLCS	Exit	Epirus Biopharma	$0	–	-7,896	–	-0.02%	–
ZGNX	Exit	Zogenix	$0	–	-291,902	–	-1.78%	–
AMRN	Exit	Amarinspons adr	$0	–	-8,087,486	–	-8.99%	–

Q2 2015

			Value		Shares		↓ Weighting
SIEN	New	Sientra	$55,151,000	–	2,199,012	–	25.03%	–
PRTO	New	Proteon	$36,039,000	–	2,017,872	–	16.36%	–
PRTK	New	Paratek	$33,524,000	–	1,301,413	–	15.22%	–
AMRN	New	Amarinspons adr	$19,814,000	–	8,087,486	–	8.99%	–
EVAR	New	Lombard Medical	$15,110,000	–	3,473,452	–	6.86%	–
CEMP	New	Cempra	$14,738,000	–	428,935	–	6.69%	–
DRNA	New	Dicerna	$13,184,000	–	945,757	–	5.98%	–
TBRA	New	Tobira	$10,159,000	–	589,244	–	4.61%	–
INNL	New	Innocoll	$7,950,000	–	555,555	–	3.61%	–
ZGNX	New	Zogenix	$3,923,000	–	291,902	–	1.78%	–
ANTH	New	Anthera	$3,767,000	–	437,994	–	1.71%	–
RGLS	New	Regulus	$3,588,000	–	327,350	–	1.63%	–
CCXI	New	Chemocentryx	$1,769,000	–	215,000	–	0.80%	–
OGXI	New	Oncogenex Pharma	$1,407,000	–	603,740	–	0.64%	–
FLKS	New	Flex Pharma	$172,000	–	10,000	–	0.08%	–
ZLCS	New	Epirus Biopharma	$45,000	–	7,896	–	0.02%	–

Q4 2014

			Value		Shares		↓ Weighting
EPRSQ	Exit	Epirus Biopharma	$0	–	-7,896	–	-0.03%	–
ANTH	Exit	Anthera	$0	–	-437,994	–	-0.50%	–
HPTX	Exit	Hyperion	$0	–	-62,500	–	-0.94%	–
OGXI	Exit	Oncogenex Pharma	$0	–	-603,740	–	-0.96%	–
RGLS	Exit	Regulus	$0	–	-327,350	–	-1.34%	–
ZGNX	Exit	Zogenix	$0	–	-2,335,218	–	-1.61%	–
CEMP	Exit	Cempra	$0	–	-714,285	–	-4.68%	–
AMRN	Exit	Amarinspons adr	$0	–	-8,087,486	–	-5.27%	–
DRNA	Exit	Dicerna	$0	–	-1,182,196	–	-8.99%	–
PTLA	Exit	Portola	$0	–	-930,682	–	-14.07%	–
SUPN	Exit	Supernus	$0	–	-2,879,328	–	-14.96%	–
EVAR	Exit	Lombard Medical	$0	–	-3,352,544	–	-15.33%	–
RNA	Exit	Prosensa	$0	–	-6,213,924	–	-31.32%	–

Q3 2014

			Value		Shares		↓ Weighting
EVAR	New	Lombard Medical	$25,647,000	–	3,352,544	–	15.33%	–
SUPN	Sell	Supernus	$25,021,000	-36.4%	2,879,328	-20.0%	14.96%	-18.2%
PTLA	Sell	Portola	$23,528,000	-35.0%	930,682	-25.0%	14.07%	-16.4%
EPRSQ	New	Epirus Biopharma	$56,000	–	7,896	–	0.03%	–
ZLCS	Exit	Zalicus	$0	–	-78,966	–	-0.04%	–

Q2 2014

			Value		Shares		↓ Weighting
RNA	New	Prosensa	$78,420,000	–	6,213,924	–	36.44%	–
SUPN	New	Supernus	$39,348,000	–	3,600,000	–	18.28%	–
PTLA	New	Portola	$36,210,000	–	1,240,912	–	16.83%	–
DRNA	New	Dicerna	$26,682,000	–	1,182,196	–	12.40%	–
AMRN	New	Amarinspons adr	$14,153,000	–	8,087,486	–	6.58%	–
CEMP	New	Cempra	$7,650,000	–	714,285	–	3.56%	–
ZGNX	New	Zogenix	$4,670,000	–	2,335,218	–	2.17%	–
RGLS	New	Regulus	$2,625,000	–	327,350	–	1.22%	–
OGXI	New	Oncogenex Pharma	$2,234,000	–	603,740	–	1.04%	–
HPTX	New	Hyperion	$1,628,000	–	62,500	–	0.76%	–
ANTH	New	Anthera	$1,485,000	–	437,994	–	0.69%	–
ZLCS	New	Zalicus	$96,000	–	78,966	–	0.04%	–

Q4 2013

			Value		Shares		↓ Weighting
ZLCS	Exit	Zalicus	$0	–	-473,800	–	-0.32%	–
HPTX	Exit	Hyperion	$0	–	-62,500	–	-0.93%	–
GWPH	Exit	GW Pharmaspons adr	$0	–	-102,200	–	-0.99%	–
ANTH	Exit	Anthera	$0	–	-437,995	–	-1.00%	–
ZGNX	Exit	Zogenix	$0	–	-2,335,218	–	-2.46%	–
OGXI	Exit	Oncogenex Pharma	$0	–	-603,740	–	-3.20%	–
CEMP	Exit	Cempra	$0	–	-714,285	–	-4.68%	–
SUPN	Exit	Supernus	$0	–	-3,600,000	–	-15.02%	–
PTLA	Exit	Portola	$0	–	-1,240,917	–	-18.92%	–
RNA	Exit	Prosensa	$0	–	-6,213,924	–	-23.37%	–
AMRN	Exit	Amarinspons adr	$0	–	-8,087,486	–	-29.12%	–

Q3 2013

			Value		Shares		↓ Weighting
RNA	New	Prosensa	$41,012,000	–	6,213,924	–	23.37%	–
ANTH	Sell	Anthera	$1,756,000	+1.7%	437,995	-87.5%	1.00%	-24.7%
ALNY	Exit	Alnylam	$0	–	-313,053	–	-7.45%	–

Q2 2013

			Value		Shares		↓ Weighting
AMRN	New	Amarinspons adr	$46,827,000	–	8,087,486	–	36.03%	–
PTLA	New	Portola	$30,502,000	–	1,240,917	–	23.47%	–
SUPN	New	Supernus	$23,184,000	–	3,600,000	–	17.84%	–
ALNY	New	Alnylam	$9,689,000	–	313,053	–	7.45%	–
OGXI	New	Oncogenex Pharma	$5,917,000	–	603,740	–	4.55%	–
CEMP	New	Cempra	$5,593,000	–	714,285	–	4.30%	–
ZGNX	New	Zogenix	$4,017,000	–	2,335,218	–	3.09%	–
ANTH	New	Anthera	$1,727,000	–	3,503,956	–	1.33%	–
HPTX	New	Hyperion	$1,376,000	–	62,500	–	1.06%	–
GWPH	New	GW Pharma (US)ads	$879,000	–	102,200	–	0.68%	–
ZLCS	New	Zalicus	$268,000	–	473,800	–	0.21%	–

Compare quarters

Export Abingworth LLP's holdings